Nick Stone | Head, Global Investor Relations |
Emma Walmsley | CEO & Director |
Luke Miels | Chief Commercial Officer |
Deborah Waterhouse | CEO, ViiV Healthcare |
Brian McNamara | CEO, GSK Consumer Healthcare |
Iain Mackay | CFO & Executive Director |
Hal Barron | Chief Scientific Officer, President of R&D and Director |
Roger Connor | President, Vaccines & Global Health |
James Gordon | JPMorgan Chase & Co. |
Keyur Parekh | Goldman Sachs Group |
Graham Parry | Bank of America Merrill Lynch |
Simon Baker | Redburn |
Timothy Anderson | Wolfe Research |
Emmanuel Papadakis | Deutsche Bank |
Jo Walton | Crédit Suisse |
Stephen Scala | Cowen and Company |
Andrew Baum | Citigroup |
Laura Sutcliffe | UBS |
Seamus Fernandez | Guggenheim Securities |
Kerry Holford | Berenberg |
Mark Purcell | Morgan Stanley |
Peter Welford | Jefferies |
Good day, and welcome, everyone, ladies and gentlemen, to the analyst call for GSK fourth quarter 2021 results. I will now hand you over to Nick Stone, Head of Global Investor Relations, who will introduce today's session. Please proceed.
Thank you, operator. Hello, everyone.